Real World Data
Late phase research, technology solutions and access to RWD are at the forefront of creating efficiencies in all stages of study design and implementation
Harnessing Technology to Maximise RWE Value
Late phase research is undergoing rapid transformation due to the impact of healthcare digitalisation and the greater availability of and access to Real World Data (RWD).
With ICON’s Real-World Intelligence™ – real world data (RWD) plus advanced expertise – you have the insights and tools to answer these important questions.
Harnessing Technology to Maximise RWE Value
With the right technology infrastructure and support, sponsors can more completely leverage RWE across the enterprise for maximum value.
Read our white paper, “On a Technology-Enabled Collision Course: Clinical Research Meets Clinical Practice through Real World Evidence” and learn how to:
- Apply Real World Intelligence™ to drive RWE generation
- Enhance trial planning and recruitment using EHRs
- Identify the emerging applications of RWD that can increase research efficiency
- Implement a technological infrastructure to maximise the value of RWD.
Meeting Evidentiary Needs with EHRs
Real World Data from Electronic Health Records can enhance your late phase research studies while decreasing study costs.
RWD-powered, post-marketing studies require fewer resources and EHRs are an efficient data source to support observational studies. Retrospective and prospective analyses, as well as case-control cross-sectional studies, can be more cost-effectively performed using EHR data.
An EHR system can also be used as the information backbone of Pragmatic clinical trials by supporting recruitment efforts and automatically capturing outcomes data.
Read our whitepaper: Meeting Evidentiary Needs with Electronic Health Records white paper
Reduce the Cost of Post-Market Surveillance with Real-World Data
Real-World Evidence (RWE) is derived from Real World Data (RWD), and early use of Real World Evidence can cut post-marketing study costs and Medical Device time-to-market.
Devices are especially good candidates for early RWE use since evidence collected in the context of actual patient care from previously approved versions or similar devices often can be used to supplement findings from clinical trials of the latest version in development.
Read our blog on how RWE can improve efficiency across the development continuum or download our two case studies
RWD and Alzheimer's
RWD such as sleep quality and quantity have clinical relevance in Alzheimer's disease, providing objective measures of sleep and activity patterns that are not subject to patient recall bias. Review the use of wearables in Alzheimer’s disease to provide objective measures of sleep and activity patterns that are not subject to patient recall bias.